MedTrace Logo

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

NCT02170623 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-06-23

No results posted yet for this study

Summary

Study to assess the amount of BIBR 953 ZW in urine and concentrations in plasma after administration of 50 mg of BIBR 1048 bid over three days each administered as two experimental formulations relative to drinking solution with and without coadministration of 40 mg Pantoprazole.

Conditions

  • Healthy

Interventions

DRUG

BIBR 1048 MS Capsule I

25 mg BIBR 1048 MS

DRUG

BIBR 1048 MS Capsule K

50 mg BIBR 1048 MS

DRUG

Pantoprazole

40 mg pantoprazole

DRUG

BIBR 1048 MS drinking solution

50 mg BIBR 1048 MS powder plus solution

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2002-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02170623 on ClinicalTrials.gov